Index RUT P/E - EPS (ttm) -3.48 Insider Own 12.10% Shs Outstand 74.40M Perf Week -0.58%
Market Cap 4.37B Forward P/E - EPS next Y -0.43 Insider Trans -4.72% Shs Float 65.39M Perf Month 66.43%
Income -258.13M PEG - EPS next Q -0.74 Inst Own 106.90% Short Float 22.03% Perf Quarter 68.55%
Sales 191.59M P/S 22.78 EPS this Y 35.89% Inst Trans 2.86% Short Ratio 7.40 Perf Half Y 52.17%
Book/sh 6.47 P/B 9.01 EPS next Y 80.80% ROA -39.32% Short Interest 14.40M Perf Year 19.32%
Cash/sh 4.11 P/C 14.17 EPS next 5Y - ROE -46.62% 52W Range 28.21 - 62.00 Perf YTD 61.22%
Dividend Est. - P/FCF - EPS past 5Y -24.25% ROI -52.97% 52W High -6.05% Beta 0.85
Dividend TTM - Quick Ratio 3.70 Sales past 5Y 663.47% Gross Margin 91.64% 52W Low 106.49% ATR (14) 3.71
Dividend Ex-Date - Current Ratio 3.81 EPS Y/Y TTM 30.06% Oper. Margin -145.17% RSI (14) 70.71 Volatility 4.45% 7.89%
Employees 368 Debt/Eq 0.02 Sales Y/Y TTM 3417.33% Profit Margin -134.73% Recom 1.12 Target Price 72.88
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 19.06% Payout - Rel Volume 1.81 Prev Close 59.93
Sales Surprise 7.67% EPS Surprise -47.08% Sales Q/Q 1029.96% Earnings Feb 20 BMO Avg Volume 1.95M Price 58.25
SMA20 25.47% SMA50 42.11% SMA200 52.94% Trades
Volume 3,530,569 Change -2.80%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-24 Initiated Evercore ISI
Outperform
$60
Feb-05-24 Initiated Guggenheim
Buy
$75
Dec-01-22 Initiated BofA Securities
Buy
$45
Jan-19-21 Reiterated H.C. Wainwright
Buy
$87 → $101
Oct-29-20 Reiterated H.C. Wainwright
Buy
$58 → $73
May-05-20 Initiated Barclays
Overweight
$48
Mar-19-20 Upgrade H.C. Wainwright
Neutral → Buy
$40 → $60
Mar-04-20 Downgrade H.C. Wainwright
Buy → Neutral
$40
Jan-21-20 Reiterated H.C. Wainwright
Buy
$34 → $40
Dec-04-19 Initiated H.C. Wainwright
Buy
Oct-08-19 Initiated Wedbush
Outperform
$33
Oct-08-19 Initiated JP Morgan
Overweight
$32
Oct-08-19 Initiated Goldman
Buy
$37
Oct-08-19 Initiated Cowen
Outperform
Show Previous Ratings
Feb-20-25 09:01AM
06:30AM
Feb-19-25 08:00AM
Feb-18-25 05:38AM
(Pharmaceutical Business Review)
Feb-13-25 11:05AM
11:00AM
Loading…
11:00AM
10:50AM
Feb-11-25 08:20PM
05:27PM
02:07AM
(The Wall Street Journal)
Jan-30-25 07:00AM
Jan-13-25 02:47PM
(Investor's Business Daily) -13.93%
06:30AM
Jan-09-25 08:40AM
Jan-08-25 02:54PM
(Investor's Business Daily)
07:26AM
Loading…
07:26AM
Jan-03-25 06:30AM
Nov-26-24 07:00AM
Nov-14-24 08:00AM
Nov-13-24 02:10AM
Nov-12-24 09:25AM
06:43AM
06:30AM
Nov-11-24 07:08AM
07:00AM
06:30AM
Nov-07-24 06:30AM
Nov-05-24 07:00AM
Oct-22-24 07:00AM
Oct-09-24 05:12PM
07:00PM
Loading…
Sep-04-24 07:00PM
Aug-28-24 06:30AM
Aug-07-24 06:30AM
Jul-29-24 06:30AM
Jul-23-24 07:00AM
Jul-12-24 11:27AM
Jul-02-24 12:12PM
Jul-01-24 06:30AM
Jun-06-24 02:34AM
02:34AM
02:34AM
Jun-05-24 07:00AM
May-23-24 05:13PM
May-08-24 07:00AM
May-03-24 03:18AM
May-02-24 10:53AM
07:45AM
06:30AM
Apr-24-24 01:31PM
Apr-18-24 07:00AM
Mar-04-24 06:30AM
Feb-29-24 08:30AM
Feb-27-24 07:12AM
06:30AM
Feb-22-24 07:00AM
Feb-07-24 02:42AM
Feb-05-24 11:26PM
Jan-31-24 07:00AM
Jan-08-24 06:30AM
Dec-21-23 07:00AM
Dec-08-23 04:05PM
Dec-05-23 12:32AM
Dec-04-23 04:13PM
Nov-29-23 07:00AM
Nov-28-23 04:41PM
04:03PM
(Investor's Business Daily)
Nov-27-23 06:04PM
Nov-16-23 06:30AM
Nov-02-23 07:54AM
06:30AM
Nov-01-23 06:30AM
Sep-11-23 06:30AM
Aug-02-23 06:30AM
Jun-28-23 08:29PM
Jun-07-23 07:00AM
Jun-05-23 06:30AM
May-30-23 06:30AM
May-25-23 05:05PM
(GlobeNewswire) -7.13%
-7.51%
May-24-23 07:00AM
May-11-23 12:14PM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-17-23 02:32PM
02:30PM
Mar-08-23 05:05PM
Mar-01-23 07:00AM
Feb-28-23 06:30AM
Feb-27-23 06:30AM
Jan-09-23 06:30AM
Jan-03-23 07:00AM
Dec-27-22 06:30AM
Nov-22-22 07:00AM
Nov-03-22 06:30AM
Nov-01-22 11:07AM
Sep-29-22 06:30AM
Sep-10-22 10:30AM
Sep-07-22 09:56AM
09:55AM
Aug-19-22 06:30AM
Aug-04-22 06:30AM
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bhavesh Ashar Officer Feb 20 '25 Proposed Sale 61.38 16,090 987,604 Feb 20 04:18 PM Islam Saqib Chief Executive Officer Feb 14 '25 Sale 59.92 10,672 639,490 1,063,953 Feb 19 04:50 PM LYNCH DANIEL Director Feb 14 '25 Sale 60.00 400 24,000 130,544 Feb 19 04:49 PM DANIEL LYNCH Director Feb 14 '25 Proposed Sale 58.59 48,000 2,812,320 Feb 14 04:21 PM Pichl Daniel Chief People Officer Feb 10 '25 Option Exercise 27.64 29,750 822,290 80,512 Feb 12 08:01 PM Pichl Daniel Chief People Officer Feb 10 '25 Sale 54.36 29,750 1,617,329 50,762 Feb 12 08:01 PM LYNCH DANIEL Director Feb 10 '25 Sale 54.46 175,000 9,530,351 130,944 Feb 12 07:59 PM Islam Saqib Chief Executive Officer Feb 10 '25 Sale 53.30 48,000 2,558,237 1,002,502 Feb 12 07:58 PM Hambleton Julie Director Feb 10 '25 Option Exercise 32.27 13,774 444,487 17,869 Feb 12 07:57 PM Hambleton Julie Director Feb 10 '25 Sale 53.01 13,774 730,207 4,095 Feb 12 07:57 PM Edris Badreddin Chief Operating Officer Feb 10 '25 Sale 53.13 30,000 1,593,795 189,712 Feb 12 07:55 PM Saqib Islam Officer Feb 10 '25 Proposed Sale 53.30 137,000 7,301,552 Feb 10 04:38 PM DANIEL LYNCH Director Feb 10 '25 Proposed Sale 40.28 175,000 7,049,000 Feb 10 04:29 PM Daniel Pichl Officer Feb 10 '25 Proposed Sale 54.36 29,750 1,617,329 Feb 10 04:13 PM Julie Hambleton Board Member Feb 10 '25 Proposed Sale 53.01 13,774 730,207 Feb 10 04:09 PM Badreddin Edris Officer Feb 10 '25 Proposed Sale 41.00 50,000 2,050,000 Feb 10 04:08 PM Edris Badreddin Chief Operating Officer Dec 03 '24 Sale 41.97 20,000 839,336 209,600 Dec 05 06:14 PM Islam Saqib Chief Executive Officer Dec 02 '24 Sale 41.37 49,000 2,027,357 1,014,368 Dec 04 04:23 PM Islam Saqib Chief Executive Officer Sep 03 '24 Sale 40.57 49,000 1,988,033 1,063,368 Sep 04 04:05 PM Edris Badreddin Chief Operating Officer Sep 03 '24 Sale 40.65 20,000 812,954 229,600 Sep 04 04:05 PM Badreddin Edris Officer Sep 03 '24 Proposed Sale 41.78 50,000 2,089,000 Sep 03 04:09 PM Saqib Islam Officer Sep 03 '24 Proposed Sale 41.58 146,000 6,070,680 Sep 03 04:07 PM Islam Saqib Chief Executive Officer Jun 03 '24 Sale 39.90 49,000 1,955,113 1,112,368 Jun 05 04:08 PM Hambleton Julie Director Jun 03 '24 Sale 40.03 4,648 186,048 4,095 Jun 05 04:08 PM Edris Badreddin Chief Operating Officer Jun 03 '24 Sale 40.07 20,000 801,372 249,600 Jun 05 04:07 PM
Index RUT P/E - EPS (ttm) -3.65 Insider Own 72.79% Shs Outstand 34.06M Perf Week 0.73%
Market Cap 82.06M Forward P/E - EPS next Y -0.95 Insider Trans -0.04% Shs Float 16.18M Perf Month -18.82%
Income -219.84M PEG - EPS next Q -0.71 Inst Own 22.81% Short Float 5.93% Perf Quarter -85.03%
Sales 2.92M P/S 28.10 EPS this Y 32.32% Inst Trans -38.41% Short Ratio 2.02 Perf Half Y -86.12%
Book/sh 1.33 P/B 1.04 EPS next Y 70.11% ROA -56.45% Short Interest 0.96M Perf Year -91.42%
Cash/sh 3.68 P/C 0.37 EPS next 5Y 48.60% ROE -132.11% 52W Range 1.26 - 22.50 Perf YTD -77.41%
Dividend Est. - P/FCF - EPS past 5Y -44.65% ROI -186.14% 52W High -93.87% Beta 0.34
Dividend TTM - Quick Ratio 5.22 Sales past 5Y 24.81% Gross Margin -206.37% 52W Low 9.52% ATR (14) 0.25
Dividend Ex-Date - Current Ratio 5.22 EPS Y/Y TTM 26.89% Oper. Margin -7557.54% RSI (14) 26.22 Volatility 10.14% 8.77%
Employees 224 Debt/Eq 0.58 Sales Y/Y TTM 57.64% Profit Margin -7534.03% Recom 3.20 Target Price 4.47
Option/Short Yes / Yes LT Debt/Eq 0.50 EPS Q/Q 2.66% Payout - Rel Volume 0.37 Prev Close 1.39
Sales Surprise 121.17% EPS Surprise -26.25% Sales Q/Q 1.38% Earnings Nov 08 BMO Avg Volume 475.55K Price 1.38
SMA20 -6.47% SMA50 -64.87% SMA200 -85.17% Trades
Volume 177,707 Change -0.72%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-10-25 Downgrade Stifel
Buy → Hold
$27 → $2.50
Jan-10-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$20 → $1.50
Jan-10-25 Downgrade Morgan Stanley
Equal-Weight → Underweight
$12 → $2
Jan-10-25 Downgrade Guggenheim
Buy → Neutral
Jan-10-25 Downgrade BMO Capital Markets
Outperform → Market Perform
$21 → $2
Dec-06-24 Initiated BMO Capital Markets
Outperform
$21
Oct-01-24 Downgrade Truist
Buy → Hold
$24 → $12
Oct-01-24 Downgrade JP Morgan
Neutral → Underweight
$12 → $9
Feb-09-24 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed Jefferies
Buy
$61 → $55
Oct-17-22 Initiated JP Morgan
Neutral
$27
Aug-29-22 Initiated BofA Securities
Buy
$34
Dec-13-21 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade Wedbush
Neutral → Outperform
Aug-26-21 Initiated Morgan Stanley
Overweight
$100
Jan-29-21 Initiated RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade Wedbush
Outperform → Neutral
Show Previous Ratings
Feb-05-25 09:35AM
Jan-11-25 10:55AM
Jan-10-25 12:43PM
07:55AM
06:43AM
01:00PM
Loading…
Jan-09-25 01:00PM
10:00AM
Nov-08-24 08:00AM
07:00AM
Nov-04-24 07:00AM
Oct-01-24 05:09PM
04:03PM
(Investor's Business Daily)
02:39PM
11:40AM
09:52AM
08:00AM
Loading…
08:00AM
Sep-30-24 04:01PM
Sep-18-24 09:33AM
Sep-10-24 04:05PM
Aug-22-24 12:00PM
Aug-14-24 08:00AM
07:00AM
Jul-12-24 09:35AM
May-29-24 07:00AM
May-10-24 02:38PM
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM
04:10PM
May-07-24 07:00AM
10:00AM
Loading…
May-03-24 10:00AM
Apr-30-24 12:00PM
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
(GlobeNewswire) -7.06%
-10.66%
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
(GlobeNewswire) +5.92%
-22.13%
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Weber Steven PRINCIPAL ACCOUNTING OFFICER Jan 15 '25 Sale 1.70 1,122 1,907 30,582 Jan 17 05:54 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Dec 16 '24 Sale 7.48 539 4,032 31,704 Dec 18 07:12 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Dec 16 '24 Sale 7.48 1,063 7,951 78,041 Dec 18 07:11 PM Harler Mary Beth Chief Executive Officer Dec 16 '24 Sale 7.48 1,708 12,776 347,032 Dec 18 07:11 PM Tahir Misbah CHIEF FINANCIAL OFFICER Dec 16 '24 Sale 7.48 1,708 12,776 187,653 Dec 18 07:10 PM Fred Schwarzer Former Officer and Director Dec 16 '24 Proposed Sale 7.17 32,250 231,232 Dec 16 05:36 PM Bruce Keyt Former Officer Dec 16 '24 Proposed Sale 7.17 18,762 134,524 Dec 16 05:34 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Sep 13 '24 Sale 11.54 469 5,412 25,543 Sep 17 08:58 PM Takimoto Chris H CHIEF MEDICAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 154,331 Sep 17 08:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 122,694 Sep 17 08:54 PM Schwarzer Fred CEO AND PRESIDENT Sep 13 '24 Sale 11.54 3,946 45,532 250,124 Sep 17 08:52 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 242,948 Sep 17 08:50 PM Harler Mary Beth Head, Research & Autoimmunity Sep 13 '24 Sale 11.54 1,487 17,158 163,740 Sep 17 08:44 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Sep 13 '24 Sale 11.54 925 10,673 79,104 Sep 17 08:42 PM Hambleton Julie Director Jul 25 '24 Option Exercise 1.39 15,132 21,033 17,132 Jul 29 05:45 PM Hambleton Julie Director Jul 25 '24 Sale 14.00 15,132 211,848 2,000 Jul 29 05:45 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Jun 14 '24 Sale 7.58 495 3,750 26,012 Jun 18 07:45 PM Takimoto Chris H CHIEF MEDICAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 95,818 Jun 18 07:44 PM Tahir Misbah CHIEF FINANCIAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 88,848 Jun 18 07:43 PM Schwarzer Fred CEO AND PRESIDENT Jun 14 '24 Sale 7.58 4,164 31,544 254,070 Jun 18 07:42 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Jun 14 '24 Sale 7.58 1,106 8,378 197,769 Jun 18 07:41 PM Harler Mary Beth Head, Research & Autoimmunity Jun 14 '24 Sale 7.58 1,570 11,893 85,227 Jun 18 07:40 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Jun 14 '24 Sale 7.58 977 7,401 60,029 Jun 18 07:38 PM BAKER BROS. ADVISORS LP Director Mar 26 '24 Buy 8.26 270,000 2,230,767 3,638,533 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 28 '24 Buy 9.62 97,473 937,632 3,753,480 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 27 '24 Buy 9.24 27,844 257,170 3,664,073 Mar 28 07:04 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 13 '24 Sale 9.88 529 5,224 26,971 Mar 15 07:57 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '24 Sale 10.17 464 4,719 26,507 Mar 15 07:57 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.88 2,889 28,529 96,923 Mar 15 07:55 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 14 '24 Sale 10.17 2,535 25,782 94,388 Mar 15 07:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 13 '24 Sale 9.88 2,897 28,608 92,961 Mar 15 07:53 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '24 Sale 10.17 2,543 25,864 90,418 Mar 15 07:53 PM Schwarzer Fred CEO AND PRESIDENT Mar 13 '24 Sale 9.88 4,765 47,055 220,833 Mar 15 07:51 PM Schwarzer Fred CEO AND PRESIDENT Mar 14 '24 Sale 10.17 4,182 42,533 216,651 Mar 15 07:51 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 13 '24 Sale 9.88 2,101 20,748 173,700 Mar 15 07:49 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 14 '24 Sale 10.17 1,844 18,754 171,856 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 13 '24 Sale 9.88 1,798 17,756 62,584 Mar 15 07:48 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '24 Sale 10.17 1,578 16,049 61,006 Mar 15 07:48 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 01 '24 Option Exercise 0.93 3,026 2,814 4,039 Mar 05 07:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
